Fresenius Medical Care


Worry lines might become deeper

22/11/22 -"FMC’s troubled US business is facing increasing difficulties which will make finding a solution more expensive. In general, the struggle to recruit nurses, i.e. medical staff, will intensify in the ..."

Pages
62
Language
English
Published on
22/11/22
You may also be interested by these reports :
28/07/26
Philips’ Q2 sales surpassed expectations, with profitability excluding one-offs meeting forecasts. The 2026 guidance was reaffirmed. However, ...

24/07/26
Sartorius reported mixed Q2 26 numbers, with revenue below consensus (-2.3%) but underlying EBITDA slightly ahead (+0.5%). Equipment inflected as ...

23/07/26
Sartorius Stedim Biotech reported mixed Q2 26 numbers, with revenue below consensus (-2.8%) but underlying EBITDA ahead (+1.1%). The miss is largely ...

17/07/26
We have revised our earnings estimates downwards and applied a 20% discount to peer-based valuation metrics to account for business challenges. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO